
The U.S. FDA has approved Regeneron (REGN.O) and Sanofi's (SASY.PA) Dupixent for treating eosinophilic esophagitis (EOE) in children aged one to 11, weighing at least 15 kg. About 21,000 U.S. children under 12 have EOE, with 9,000 unsatisfactorily responding to current treatments. Dupixent, priced at $3,803.20 per carton, treats various inflammatory conditions and earned $8.68 billion globally in 2022. The approval follows a study showing reduced intensity in 66% of children below 12. It's the first drug for younger EOE patients, aiming to prevent esophageal scarring. Regeneron and Sanofi seek FDA approval for Dupixent to treat COPD.
Like
Save
Share